Literature DB >> 18648006

NUP98-HOX translocations lead to myelodysplastic syndrome in mice and men.

Christopher Slape1, Ying Wei Lin, Helge Hartung, Zhenhua Zhang, Linda Wolff, Peter D Aplan.   

Abstract

The myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, peripheral blood cytopenias, dysplasia, and a propensity for transformation to acute myeloid leukemia (AML). A wide spectrum of genetic aberrations has been associated with MDS, including chromosomal translocations involving the NUP98 gene, most commonly leading to fusions of NUP98 with abd-b group HOX genes, including HOXD13. We used vav regulatory elements to direct expression of a NUP98-HOXD13 (NHD13) fusion gene in hematopoietic tissues. NHD13 transgenic mice faithfully recapitulate all the key features of MDS, including peripheral blood cytopenias, bone marrow dysplasia and apoptosis, and transformation to acute leukemia. The MDS that develops in NHD13 transgenic mice is highly lethal; within 14 months, 90% of the mice died of either leukemic transformation or severe anemia and leukopenia due to progressive MDS. These mice provide a preclinical model that can be used for the evaluation of MDS therapy and biology.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18648006      PMCID: PMC2518060          DOI: 10.1093/jncimonographs/lgn014

Source DB:  PubMed          Journal:  J Natl Cancer Inst Monogr        ISSN: 1052-6773


  22 in total

Review 1.  Focus on acute leukemias.

Authors:  D Gary Gilliland; Martin S Tallman
Journal:  Cancer Cell       Date:  2002-06       Impact factor: 31.743

2.  Comparative genomic hybridization using oligonucleotide microarrays and total genomic DNA.

Authors:  Michael T Barrett; Alicia Scheffer; Amir Ben-Dor; Nick Sampas; Doron Lipson; Robert Kincaid; Peter Tsang; Bo Curry; Kristin Baird; Paul S Meltzer; Zohar Yakhini; Laurakay Bruhn; Stephen Laderman
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-10       Impact factor: 11.205

Review 3.  NUP98 gene rearrangements and the clonal evolution of chronic myelogenous leukemia.

Authors:  H G Ahuja; L Popplewell; L Tcheurekdjian; M L Slovak
Journal:  Genes Chromosomes Cancer       Date:  2001-04       Impact factor: 5.006

4.  A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9.

Authors:  Ajeeta B Dash; Ifor R Williams; Jeffery L Kutok; Michael H Tomasson; Ema Anastasiadou; Kathleen Lindahl; Shaoguang Li; Richard A Van Etten; Julian Borrow; David Housman; Brian Druker; D Gary Gilliland
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

5.  Potential role for DNA topoisomerase II poisons in the generation of t(11;20)(p15;q11) translocations.

Authors:  H G Ahuja; C A Felix; P D Aplan
Journal:  Genes Chromosomes Cancer       Date:  2000-10       Impact factor: 5.006

Review 6.  Genome-wide analysis of DNA methylation changes in human malignancies.

Authors:  C Plass; D J Smiraglia
Journal:  Curr Top Microbiol Immunol       Date:  2006       Impact factor: 4.291

7.  Promoter elements of vav drive transgene expression in vivo throughout the hematopoietic compartment.

Authors:  S Ogilvy; D Metcalf; L Gibson; M L Bath; A W Harris; J M Adams
Journal:  Blood       Date:  1999-09-15       Impact factor: 22.113

8.  The (4;11)(q21;p15) translocation fuses the NUP98 and RAP1GDS1 genes and is recurrent in T-cell acute lymphocytic leukemia.

Authors:  D J Hussey; M Nicola; S Moore; G B Peters; A Dobrovic
Journal:  Blood       Date:  1999-09-15       Impact factor: 22.113

9.  Haemangioblast commitment is initiated in the primitive streak of the mouse embryo.

Authors:  Tara L Huber; Valerie Kouskoff; H Joerg Fehling; James Palis; Gordon Keller
Journal:  Nature       Date:  2004-12-02       Impact factor: 49.962

10.  NUP98-HOXD13 transgenic mice develop a highly penetrant, severe myelodysplastic syndrome that progresses to acute leukemia.

Authors:  Ying-Wei Lin; Christopher Slape; Zhenhua Zhang; Peter D Aplan
Journal:  Blood       Date:  2005-03-08       Impact factor: 22.113

View more
  16 in total

1.  Amino-terminal enhancer of split (AES) interacts with the oncoprotein NUP98-HOXA9 and enhances its transforming ability.

Authors:  Nayan J Sarma; Nabeel R Yaseen
Journal:  J Biol Chem       Date:  2011-09-21       Impact factor: 5.157

Review 2.  NUP98 gene fusions and hematopoietic malignancies: common themes and new biologic insights.

Authors:  Sheryl M Gough; Christopher I Slape; Peter D Aplan
Journal:  Blood       Date:  2011-09-26       Impact factor: 22.113

Review 3.  Mouse models of myelodysplastic syndromes.

Authors:  Sarah H Beachy; Peter D Aplan
Journal:  Hematol Oncol Clin North Am       Date:  2010-04       Impact factor: 3.722

4.  Sphingolipid metabolism determines the therapeutic efficacy of nanoliposomal ceramide in acute myeloid leukemia.

Authors:  Brian M Barth; Weiyuan Wang; Paul T Toran; Todd E Fox; Charyguly Annageldiyev; Regina M Ondrasik; Nicole R Keasey; Timothy J Brown; Viola G Devine; Emily C Sullivan; Andrea L Cote; Vasiliki Papakotsi; Su-Fern Tan; Sriram S Shanmugavelandy; Tye G Deering; David B Needle; Stephan T Stern; Junjia Zhu; Jason Liao; Aaron D Viny; David J Feith; Ross L Levine; Hong-Gang Wang; Thomas P Loughran; Arati Sharma; Mark Kester; David F Claxton
Journal:  Blood Adv       Date:  2019-09-10

5.  Delineating domains and functions of NUP98 contributing to the leukemogenic activity of NUP98-HOX fusions.

Authors:  Eric Yung; Sanja Sekulovic; Bob Argiropoulos; Courteney K Lai; Malina Leung; Tobias Berg; Sarah Vollett; Vicky Chi-Dan Chang; Adrian Wan; Sandy Wong; R Keith Humphries
Journal:  Leuk Res       Date:  2010-12-03       Impact factor: 3.156

6.  Knock-in of a FLT3/ITD mutation cooperates with a NUP98-HOXD13 fusion to generate acute myeloid leukemia in a mouse model.

Authors:  Sarah Greenblatt; Li Li; Christopher Slape; Bao Nguyen; Rachel Novak; Amy Duffield; David Huso; Stephen Desiderio; Michael J Borowitz; Peter Aplan; Donald Small
Journal:  Blood       Date:  2012-02-08       Impact factor: 22.113

7.  Global H3K4me3 genome mapping reveals alterations of innate immunity signaling and overexpression of JMJD3 in human myelodysplastic syndrome CD34+ cells.

Authors:  Y Wei; R Chen; S Dimicoli; C Bueso-Ramos; D Neuberg; S Pierce; H Wang; H Yang; Y Jia; H Zheng; Z Fang; M Nguyen; I Ganan-Gomez; B Ebert; R Levine; H Kantarjian; G Garcia-Manero
Journal:  Leukemia       Date:  2013-03-29       Impact factor: 11.528

Review 8.  Engineering mouse models with myelodysplastic syndrome human candidate genes; how relevant are they?

Authors:  Stephanie Beurlet; Christine Chomienne; Rose Ann Padua
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

9.  Depletion of cytotoxic T-cells does not protect NUP98-HOXD13 mice from myelodysplastic syndrome but reveals a modest tumor immunosurveillance effect.

Authors:  Sheryl M Gough; Yang Jo Chung; Peter D Aplan
Journal:  PLoS One       Date:  2012-05-11       Impact factor: 3.240

10.  Mutant Idh2 Cooperates with a NUP98-HOXD13 Fusion to Induce Early Immature Thymocyte Precursor ALL.

Authors:  Liat Goldberg; Vijay Negi; Yang Jo Chung; Masahiro Onozawa; Yuelin J Zhu; Robert L Walker; Rachel Pierce; Daxesh P Patel; Kristopher W Krausz; Frank J Gonzalez; Margaret A Goodell; Benjamin A T Rodriguez; Paul S Meltzer; Peter D Aplan
Journal:  Cancer Res       Date:  2021-07-28       Impact factor: 13.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.